A practical reference on acetylated peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
In May 2025, the government announced this decision, citing a worsening global economic outlook and the need to reallocate the remaining 157-billion-baht budget to more urgent stimulus measures, such as infrastructure development and tourism promotion. Paetongtarn has publicly insisted that the postponement is not a cancellation and that the government remains committed to fulfilling its promise once economic conditions improve. The policy has been a focal point of her premiership, drawing both support for its potential to aid households and strong criticism from economists for its high cost and debated effectiveness as a stimulus tool.
=== Journal articles === Bridge, D; Cunningham, C W; Schierwater, B; DeSalle, R; Buss, L W (15 September 1992). "Class-level relationships in the phylum Cnidaria: evidence from mitochondrial genome structure". Proceedings of the National Academy of Sciences. 89 (18): 8750–8753. Bibcode:1992PNAS...89.8750B. doi:10.1073/pnas.89.18.8750. PMC 49998. PMID 1356268. Bridge, D; Cunningham, CW; DeSalle, R; Buss, LW (July 1995). "Class-level relationships in the phylum Cnidaria: molecular and morphological evidence". Molecular Biology and Evolution. 12 (4): 679–689. doi:10.1093/oxfordjournals.molbev.a040246. PMID 7659022. Fautin, Daphne Gail (October 2002). "Reproduction of Cnidaria". Canadian Journal of Zoology. 80 (10): 1735–1754. Bibcode:2002CaJZ...80.1735F. doi:10.1139/z02-133. hdl:1808/5373. Mackie, G O (October 2002). "What's new in cnidarian biology?". Canadian Journal of Zoology. 80 (10): 1649–1653. Bibcode:2002CaJZ...80.1649M. doi:10.1139/z02-138. Schuchert, P. (27 April 2009). "Phylogenetic analysis of the Cnidaria". Journal of Zoological Systematics and Evolutionary Research. 31 (3): 161–173. doi:10.1111/j.1439-0469.1993.tb00187.x. Kass-Simon, G; Scappaticci, Jr., A A (October 2002). "The behavioral and developmental physiology of nematocysts". Canadian Journal of Zoology. 80 (10): 1772–1794. Bibcode:2002CaJZ...80.1772K. doi:10.1139/z02-135. J. Zrzavý (2001). "The interrelationships of metazoan parasites: a review of phylum- and higher-level hypotheses from recent morphological and molecular phylogenetic analyses". Folia Parasitologica. 48 (2): 81–103.
=== HLX === Following the release of Half-Life: Alyx in 2020, dataminers examining updates to the Source 2 engine discovered that Valve was developing a non-VR game codenamed HLX. On December 31, 2024, Mike Shapiro, the voice actor for the G-Man, posted a cryptic message on X suggesting "unexpected surprises" in the new year. In April, it was reported that HLX was being playtested and would be a sequel to Episode Two. Industry insiders, dataminers and leakers reported that Valve was planning a 2025 announcement for HLX. In December, the Insider Gaming senior editor Mike Straw said HLX was planned as a launch game for Valve's Steam Machine hardware, and the announcement had been delayed by the rising cost of RAM.
Sources: en.wikipedia.org
for the synthesis of S-Nitrosoglutathione see Hart, T.W., 1985. Some observations concerning the S-nitroso and S-phenylsulphonyl derivatives of L-cysteine and glutathione. Tetrahedron Letters, 26(16), pp.2013-2016.
These variations can be attributed to factors like geographic isolation, strict border controls, lenient laws on illegal items, high prices, tight internet control, and the general accessibility of illegal goods.
== D == dactinomycin - dalton - decarboxylation reaction - delta opioid receptor - denaturation (biochemistry) - dendrite - dendritic cell - dendritic spine - deoxyribonucleoprotein - deoxyribose - desmopressin - deuterium - developmental biology - dialysis (chemical) - diffusion - dimer - dinucleotide repeat - diploid - disaccharide - dissociation constant - disulfide bond - disulfide bridge - DNA - DNA fragmentation - DNA replication - DNA sequence - DNA topology - DNA transposable element - DNA virus - DNA-binding protein - dopamine D1 receptor - dopamine D2 receptor - dopamine receptor - double helix - Drosophila - drugs - dynorphin
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.